Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01217931 · ClinicalTrials.gov registry record · Phase 2
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
A Phase 2 study of Kidney Cancer, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT01217931: Active Phase 2 study of Kidney Cancer, sponsored by M.D. Anderson Cancer Center.
NCT01217931 is a Phase 2 study of Kidney Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 180 participants, below the 877-participant average among 60 other Kidney Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01217931, a Phase 2 study of Kidney Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to compare 6 different 2-drug "sequences" of everolimus, bevacizumab, or pazopanib to learn how they may affect metastatic kidney cancer. For the 2-drug sequence, participants will receive 1 of these drugs and may start taking another of these drugs after that. Researchers will also study the safety of these 2-drug sequences.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Everolimus
- DRUG Pazopanib
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2011-01-19 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01217931
The ClinicalTrials.gov registry entry for NCT01217931 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 877-participant average among 60 other Kidney Cancer trials with a reported enrollment target (79% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01217931 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01217931 about?
NCT01217931 is a clinical study titled "Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial". The goal of this clinical research study is to compare 6 different 2-drug "sequences" of everolimus, bevacizumab, or pazopanib to learn how they may affect metastatic kidney cancer. For the 2-drug sequence, participants will receive 1 of these drugs and may start taking another of these drugs after ...
What is the current status of trial NCT01217931?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2011-01-19. Estimated completion is 2028-01-31.
What conditions does trial NCT01217931 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT01217931?
The interventions under investigation include: Bevacizumab (DRUG), Everolimus (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01217931?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01217931 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.